SAN DIEGO--(BUSINESS WIRE)--April 19, 2004--Conforma Therapeutics Corporation today announced the appointment of Christopher C. LeMasters to the newly created position of Vice President, Corporate Development.
Prior to joining Conforma, Mr. LeMasters worked for six years in Corporate Business Development at Eli Lilly and Company in Indianapolis. In that role, he was responsible for the successful negotiation of numerous research and development collaborations across diverse therapeutic areas. Additionally, he led or contributed to multiple strategy development projects, and was instrumental in the redesign of Lilly's licensing processes and organization. Prior to Lilly, he was a management consultant with Coopers & Lybrand Consulting in Chicago for four years, where he led strategy consulting projects for Fortune 500 clients. He began his business career as an operational auditor for Owens-Corning Fiberglas in Toledo.
"Conforma will benefit greatly from Chris' broad strategic and business development experience," said Lawrence C. Fritz, Ph.D., president and chief executive officer of Conforma. "We expect that he will play a key role in advancing our strategic growth through in-licensing of new programs and products, and selective corporate partnering of our internally-developed drugs and technologies. I am pleased to welcome him to the Conforma management team."
Mr. LeMasters has a B.A. in Finance from Indiana University and an M.B.A. with Honors from the University of Chicago.
About Conforma Therapeutics
Conforma Therapeutics, a San Diego-based biopharmaceutical company, is focused on the design and development of novel drugs for the selective treatment of cancer. Conforma is developing drugs that target the cellular HSP90 family of molecular "chaperones" that control protein shape or conformation, including that of key signaling molecules involved in the growth and survival of tumor cells. HSP90-directed drugs selectively induce the degradation of these cancer-promoting proteins, leading to tumor cell death. In addition to cancer, Conforma's technology also promises to have applications in other areas of medicine, including inflammation, virology, and central nervous system disorders. Conforma's lead product, CNF1010, is expected to enter the clinic in 2004 for the treatment of cancer, and will be followed by a pipeline of differentiated, molecularly targeted oncology products. Additional information regarding Conforma is available at www.conformacorp.com.
Conforma Therapeutics Leah James, 858-657-0300 or
Kureczka/Martin Associates Joan Kureczka, 415-821-2413 Jkureczka@comcast.net